Access

Correspondence

Nature Medicine 15, 1112 - 1115 (2009)
doi:10.1038/nm1009-1112

CCL3L1 and HIV/AIDS susceptibility

Tanmoy Bhattacharya1,2, Jennifer Stanton3, Eun-Young Kim3, Kevin J Kunstman3, John P Phair3, Lisa P Jacobson4 & Steven M Wolinsky3

  1. Santa Fe Institute, Santa Fe, New Mexico, USA.
  2. Los Alamos National Laboratory, Los Alamos, New Mexico, USA.
  3. Division of Infectious Diseases, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  4. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

Correspondence to: Steven M Wolinsky3 e-mail: s-wolinsky@northwestern.edu

A selective advantage against infectious diseases such as HIV/AIDS is associated with differences in the genes relevant to immunity and virus replication. The CC chemokine receptor-5 (CCR5), the principal co-receptor for HIV, and its chemokine ligands, including CC chemokine ligand-3–like-1 (CCL3L1), influence the susceptibility of the CD4+ target cell to infection1.